علاج سرطان الدم/اللمفومة من الخلايا التائية البالغة من النوع الحاد أو النوع اللمفومي مع آفات ضخمة

References

DOI: 10.1016/j.annonc.2025.01.023

• Patients with acute or lymphoma-type ATLL with bulky lesions may receive intensive combination ChT [e.g. CHOP, CHOEP or hyperfractionated cyclophosphamide-vincristine-doxorubicin-dexamethasone-MTX-cytarabine (hyper-CVAD)] with or without concurrent or sequential zidovudine-IFN-a (if tolerated) [III, C; not EMA or FDA approved].
• A second-line platinum-based regimen can be considered [IV, B].
• Monotherapy with mogamulizumab (if CCR4-positive; not EMA or FDA approved), BV (if CD30-positive; not EMA or FDA approved), alemtuzumab (if CD52-positive; not EMA or FDA approved) or lenalidomide (not EMA or FDA approved) can be considered [III, B].
• Allo-HSCT (if not used in first line) should be considered in HSCT-eligible responding patients [III, A].